KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Accumulated Expenses: 2009-2018

Historic Other Accumulated Expenses for Alnylam Pharmaceuticals (ALNY) over the last 1 years, with Dec 2018 value amounting to $23.6 million.

  • Alnylam Pharmaceuticals' Other Accumulated Expenses rose 117.66% to $23.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $23.6 million, marking a year-over-year increase of 117.66%. This contributed to the annual value of $23.6 million for FY2018, which is 117.66% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $23.6 million for Q4 2018, which was up 117.66% from $10.9 million recorded in Q4 2017.
  • Over the past 5 years, Alnylam Pharmaceuticals' Other Accumulated Expenses peaked at $25.4 million during Q1 2014, and registered a low of $3.8 million during Q4 2014.
  • For the 2-year period, Alnylam Pharmaceuticals' Other Accumulated Expenses averaged around $17.2 million, with its median value being $17.2 million (2017).
  • Data for Alnylam Pharmaceuticals' Other Accumulated Expenses shows a peak YoY spiked of 117.66% (in 2018) over the last 5 years.
  • Over the past 4 years, Alnylam Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $3.8 million in 2014, then skyrocketed by 30.38% to $5.0 million in 2015, then reached $10.9 million in 2017, then soared by 117.66% to $23.6 million in 2018.
  • Its Other Accumulated Expenses was $23.6 million in Q4 2018, compared to $10.9 million in Q4 2017 and $5.0 million in Q4 2015.